Luis Diaz

Luis Diaz is a pioneer in mismatch repair deficiency and microsatellite instability as universal biomarkers for immunotherapy, contributing to the landmark agnostic approval of pembrolizumab for MSI-H tumors. His work at Memorial Sloan Kettering demonstrated that MMR-deficient tumors respond to PD-1 blockade regardless of histological origin, a paradigm-shifting finding. He has advanced liquid biopsy and circulating tumor DNA as clinical tools for detecting treatment response and cancer recurrence. His contributions have fundamentally changed how biomarker-driven immunotherapy is applied.